Pennsylvania is currently home to 3298 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Stroke Thrombectomy and Aneurysm Registry
NCT04994756
Recruiting
This international multi-center registry is used to collect existing information and outcomes for patients undergoing an operation for treatment of injuries to the brain including the blockage of blood flow to an area of the brain, an abnormal ballooning of an artery, abnormal tangling of blood vessels, abnormal formation of blood vessels, tearing of vein, and bleeding in the brain. This information is used to help predict outcomes that undergo an operation for treatment of the above-listed brai... Read More
Gender:
ALL
Ages:
Between 1 year and 120 years
Trial Updated:
12/05/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Stroke, Thromboses, Intracranial, Aneurysm, Brain
Register for Updates
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT04981795
Recruiting
The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression
NCT06510894
Recruiting
This is a pilot mechanistic study of the diagnostic utility of sodium-glucose cotransporter-1/2 inhibition (SGLT1/2) on myocardial glucose suppression on FDG PET/CT. The investigators will test whether the addition of a SGLT1/2 inhibitor (SGLT1/2i) plus the standard dietary modification (ketogenic diet) will provide enhanced myocardial glucose suppression. The primary objective is to assess rates of complete myocardial glucose suppression (MGS) with 7 days of sotagliflozin 400 mg QD among health... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/04/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cardiac Sarcoidosis
Register for Updates
Longitudinal Assessment of Brain Structure and Function in Juvenile-onset Huntington's Disease
NCT05707663
Recruiting
The goal of this observational study is to learn about brain development in Juvenile-onset Huntington's Disease (JoHD). The main questions it aims to answer are: * Is brain development different in JoHD than Adult-onset Huntington's Disease (AoHD)? * Can reliable biomarkers for JoHD be found in brain structure and function? Participants will be asked to complete cognitive tests, behavioral assessments, physical and neurologic evaluation, and MRI. Data collected will be compared to populations... Read More
Gender:
ALL
Ages:
Between 6 years and 30 years
Trial Updated:
12/04/2024
Locations: Children's Hospital of Philadelphia with the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Juvenile Huntington Disease, Juvenile-Onset Huntington Disease
Register for Updates
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
NCT05476770
Recruiting
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is pre... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
12/04/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Register for Updates
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
NCT05361174
Recruiting
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/04/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Register for Updates
Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults
NCT05108818
Recruiting
Cellular and humoral immune responses before and after seasonal influenza vaccination will be assessed. Each year, up to 100 participants will be enrolled. To study age-specific differences in immune responses, participants with various years of birth will be enrolled. The investigators hypothesize that humans with different birth years will mount antibody and cellular responses of different specificities following seasonal influenza vaccination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Influenza, Human
Register for Updates
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444
Recruiting
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: Crozer-Keystone Health System, Broomall, Pennsylvania
Conditions: Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma
Register for Updates
HoFH, the International Clinical Collaborators Registry
NCT04815005
Recruiting
Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature atherosclerotic cardiovascular disease (ASCVD). Our current knowledge about HoFH is disjointed and largely stems from relatively small case series and expert opinion. HICC (Homozygous FH International Clinical Collaborators) is a global consortium... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/04/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Homozygous Familial Hypercholesterolemia
Register for Updates
Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation
NCT03721822
Recruiting
The purpose of this research is to measure the extent of lung inflammation between different groups of participants using a radioactive tracer called \[18F\]NOS. A radioactive tracer is a type of imaging drug that is labeled with a radioactive tag and injected into the body.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
12/04/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Smoking, Cigarette, Smoking E-cigarette, Healthy Volunteer
Register for Updates
Efficacy of Sodium Glucose Transporter Inhibitor (SGLT2I) in Adult Patients with Congenital Heart Disease
NCT06260059
Recruiting
The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Magee Women's Hospital, Pittsburgh, Pennsylvania
Conditions: Adult Congenital Heart Disease, Heart Failure
Register for Updates
4D-150 in Patients With Diabetic Macular Edema
NCT05930561
Recruiting
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Erie Retina Research, Erie, Pennsylvania
Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Register for Updates